CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

“The Decipher Prostate test’s ability to help guide treatment for patients with localized prostate cancer is already proven in dozens of peer-reviewed publications and is the only molecular test to achieve ‘Level 1B’ evidence status in the most recent NCCN® Guidelines* for prostate cancer,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. “These new phase 3 data from the STAMPEDE trial now further prove the performance and utility of our test in patients with metastatic prostate cancer. We believe our test can have a tremendous positive impact on care for these patients.”

The 30-patient study reported that the Delcath Systems HEPZATO KIT™ (melphalan/Hepatic Delivery System (HDS)) provided better disease control in the liver and improved progression-free survival in patients with hepatic metastases from uveal melanoma, compared to both immunotherapy and other liver-directed therapies.

“This analytical validation study strongly complements EsoGuard’s extensive peer-reviewed, published clinical validity and clinical utility evidence base,” said Suman Verma, M.D., PhD, Chief Scientific Officer at Lucid Diagnostics. “The results demonstrate very robust analytical performance of the EsoGuard assay performed in our CLIA-certified, CAP-accredited, NY State-approved commercial laboratory.”

The funding will be used to support Jupiter Endovascular in their upcoming pivotal trial for Pulmonary Embolism and development of additional clinical applications of the Endoportal ControlTM technology.

“We are very excited about the results from this collaborative effort that have now culminated in a publication in Bone, “ said Prof. Anton Eisenhauer who is a key inventor of the CIM technology and osteolabs´ Chief Scientific Officer. “This larger subset of routine clinical samples fully supports the potential for OsteoTest to qualify as a new universal diagnostic method for early osteoporosis risk assessment and therapeutic control.”

Genprex notes the patients in the Company’s lung cancer clinical trials are being treated with the Company’s lead drug candidate, Reqorsa® (quaratusugene ozeplasmid) Gene Therapy. Two patients in the Acclaim-1 study have had prolonged Progression Free Survival (PFS) and importantly, the first treated patient in the Acclaim-3 study attained a Partial Remission (PR) from the start of maintenance therapy.